Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET409 with/without Empagliflozin in T2DM and NASH
NCT04702490Phase 2Unknown
- Sponsor
- Metacrine, Inc.
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omesdafexor in Nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Metacrine, Inc. Primary endpoint: Incidence of adverse events. Status: unknown.
02
Drugs
omesdafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04702490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702490.